Screener
Aardvark Therapeutics, Inc. AARD Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by Aardvark Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Aardvark Therapeutics, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 9:32 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210675
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Unrealized loss on short-term investments | (13) | (15) |
| Interest and dividend income | 889 | 1,175 |
| Total other income, net | 876 | 1,160 |
| Net loss | $(21,588) | $(9,310) |
| Net loss per share of common stock, basic and diluted (Note 3) | $(0.99) | $(0.71) |
| Weighted-average shares used in net loss per share calculation (Note 3) | 21,815,995 | 13,194,718 |
| Comprehensive income (loss): | ||
| Net loss | $(21,588) | $(9,310) |
Item 1. Financial Statements.
FAQ
- What is Aardvark Therapeutics, Inc.'s net income?
- Aardvark Therapeutics, Inc. (AARD) reported net income of -$21.59M in Q1 2026.
- How has Aardvark Therapeutics, Inc.'s net income changed year-over-year?
- Aardvark Therapeutics, Inc.'s net income decreased by 131.9% year-over-year, from -$9.31M to -$21.59M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Aardvark Therapeutics, Inc.'s net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude